Engelmann, Simon Udo and Pickl, Christoph and Haas, Maximilian and Kasparbauer, Felix and Rinderknecht, Emily and Kälble, Sebastian and van Rhijn, Bas W. G. and Siska, Peter J. and Decking, Sonja-Maria and Renner, Kathrin and Pichler, Renate and Burger, Maximilian and Guzvic, Miodrag and Mayr, Roman (2025) Prognostic Role of Serum IL-6 Levels in Bladder Cancer Patients and Hints of its Origin. CLINICAL GENITOURINARY CANCER, 23 (4): 102378. ISSN 1558-7673, 1938-0682
Full text not available from this repository. (Request a copy)Abstract
Interleukin-6 (IL-6) is associated with poor outcomes in bladder cancer (BC) patients, including worse overall survival (OS) and cancer-specific survival (CSS). This study analyzed serum IL-6 levels in 179 BC patients undergoing radical cystectomy and IL-6 concentrations in tumor tissue from 20 additional patients. High serum IL-6 was an independent predictor of OS and CSS, and higher levels were linked to advanced tumor stage, lymph node metastasis, and larger tumor size. Tumor tissue IL-6 was significantly elevated in muscle-invasive BC compared to early-stage tumors. These findings underscore the prognostic potential of IL-6 and its relevance in BC theranostics.<br /> Background: Interleukin-6 (IL-6) is associated with adverse clinical outcome in cancer patients. In bladder cancer (BC) patients, higher IL-6 serum levels have been linked with adverse pathologic features, worse overall survival (OS) and cancer-specific survival (CSS). IL-6 is being investigated as a therapeutic target. However, concentrations in tumor-tissue are not investigated in detail. Objective of this study is to analyze the prognostic value of IL-6 in BC patients and to investigate its concentration in tumor tissue. Methods: In this single center prospective observational study, preoperative serum samples of 179 BC patients undergoing radical cystectomy were collected between September 2019 and September 2022. Tumor-tissue of additional 20 patients was collected during transurethral resection or radical cystectomy for investigation of IL-6 in tumor tissue supernatant. IL-6 concentration was measured by ELISA. Results: Median serum IL-6 concentration was 5.4 pg/mL. High serum IL-6 was an independent predictor of OS (HR 1.95; 95% CI, 1.07-3.55; P = .03) and CSS (HR 2.31; 95% CI, 1.14-4.68; P = .02) in multivariate Cox regression analyses. Patients with advanced tumor stage, lymph node metastasis, and larger tumor size had significantly higher preoperative serum IL-6 concentration (all P < .01). In tumor tissue supernatant, IL-6 concentration was higher in muscle-invasive BC, with a median of 715.4 pg/mL, as opposed to 20.7 pg/mL in pTa tumor stage ( P < .01). Conclusions: Serum IL-6 is a strong predictor of poor survival rates and adverse pathologic features in BC patients. IL-6 concentrations in tumor tissue supernatant correlate with tumor stage. The role of IL-6 in theranostics of bladder cancer deserves more attention.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | INTERLEUKIN-6; RECEPTOR; Biomarker; Tumor microenvironment; Urothelial cancer; Immunology; Interleukin |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Hals-Nasen-Ohren-Heilkunde Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) Medicine > Lehrstuhl für Urologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 15 Oct 2026 07:47 |
| Last Modified: | 15 Oct 2026 07:47 |
| URI: | https://pred.uni-regensburg.de/id/eprint/66292 |
Actions (login required)
![]() |
View Item |

